Paula Guedes de Pinho| Oncologia| Excellence in Innovation

Posted on by sciencefatherLeave a Comment on Paula Guedes de Pinho| Oncologia| Excellence in Innovation

Prof.Paula Guedes de Pinho| Oncologia| Excellence in Innovation

PGP graduated in Pharmaceutical Sciences from the Faculty of Pharmacy of the University of Porto (FFUP) and completed a PhD in Medical and Biological Sciences at the University of Bordeaux II, France. Currently, she is a Coordinator Researcher at UCIBIO/FFUP with a permanent contract and an Affiliate Professor (with Habilitation) at the Faculty of Science of the University of Porto. She has published over 200 papers (h-index 48 – Scopus) in international peer-reviewed journals, authored 13 book chapters, and received 15 prizes or awards. PGP established the research line of Metabolomics applied to cancer biomarker discovery at the Laboratory of Toxicology of FFUP, securing funded projects for its development.

Profiles

Scopus

ORCID

Hai Huang| Prostate cancer| Best Researcher Award

Posted on by sciencefatherLeave a Comment on Hai Huang| Prostate cancer| Best Researcher Award

Prof. Hai Huang| Prostate cancer| Best Researcher Award

Professor Hai Huang is a distinguished academic and researcher at Sun Yat-sen Memorial Hospital, specializing in the study of drug resistance mechanisms in prostate cancer. His research primarily focuses on understanding how the tumor microenvironment affects resistance to androgen receptor-targeted therapies and chemotherapy, aiming to develop better treatment strategies and improve patient outcomes. With an impressive portfolio, Professor Huang has completed 30 research projects, published 97 journal articles in SCI and Scopus-indexed journals, authored 9 books, and holds 20 patents.

Profiles

Scopus

Orcid

 

📚Academic and Professional Background:

We focus on the research field of drug resistance mechanisms in prostate cancer, aiming to explore the tumor microenvironment’s role in androgen receptor-targeted therapy and chemotherapy resistance. Our work seeks to improve therapeutic strategies and patient outcomes in prostate cancer treatment.

📊 Research and Innovations:

Completed/Ongoing Research Projects:  30 , Citation Index:  (Hai Huang[Author])  AND  (Sun Yat-sen Memorial Hospital [Affiliation]) ,Consultancy/Industry Projects:  Prostate Cancer , Books Published (ISBN):  9 , Patents Published/Under Process: 20 , Journals Published (SCI, Scopus, etc.):  97

🤝 Collaborations:

Qin Jun: CAS Key Laboratory of Tissue Microenvironment and Tumor, CAS Center for Excellence in Molecular Cell Science, Shanghai Institute of Nutrition and Health, Shanghai Jiao Tong University School of Medicine (SJTUSM) & Chinese Academy of Sciences ,  Gao Dong: State Key Laboratory of Cell Biology, Shanghai Key Laboratory of Molecular Andrology, Shanghai Institute of Biochemistry and Cell Biology, Center for Excellence in Molecular Cell Science, Chinese Academy of Sciences

🏆 Professional Memberships: 

American Urological Association, European Association of Urology

🔬 Areas of Research: 

Prostate cancer treatment resistance

🏆 Contributions :

Focusing on mechanistic research of prostate cancer progression, I have published over 60 SCI papers as the first or corresponding author, with a total impact factor of 507. I have presented at numerous international urological conferences, sharing insights and advancements in prostate cancer treatment.

✍️ Self-Declaration:

I authenticate that to the best of my knowledge, the information given in this form is correct and complete. If at any time I am found to have concealed any material information, my application shall be liable to be summarily terminated without notice. I have read the terms and conditions and other policies of the Awards and agree to them.

📚 Publications :

  • 🧬 Single-cell deconvolution algorithms analysis unveils autocrine IL11-mediated resistance to docetaxel in prostate cancer via activation of the JAK1/STAT4 pathway
    • Authors: Cheng, B., Li, L., Luo, T., Lai, Y., Huang, H.
    • Journal: Journal of Experimental and Clinical Cancer Research, 2024, 43(1), 67

 

  • 🔄 Correction: The key cellular senescence related molecule RRM2 regulates prostate cancer progression and resistance to docetaxel treatment
    • Authors: Cheng, B., Li, L., Wu, Y., Du, T., Huang, H.
    • Journal: Cell and Bioscience, 2024, 14(1), 17

 

  • 🔬 A protein-encoding CCDC7 circular RNA inhibits the progression of prostate cancer by up-regulating FLRT3
    • Authors: Wang, Q., Cheng, B., Singh, S., Li, H., Huang, H.
    • Journal: npj Precision Oncology, 2024, 8(1), 11.

 

  • 💊 Redox responsive polymeric nanoparticles enhance the efficacy of cyclin dependent kinase 7 inhibitor for enhanced treatment of prostate cancer
    • Authors: Tao, Y., Dai, C., Xie, Z., Wu, J., Huang, H.
    • Journal: Chinese Chemical Letters, 2024, 35(8), 109170

 

  • 🧩 Cancer-associated fibroblasts promote enzalutamide resistance and PD-L1 expression in prostate cancer through CCL5-CCR5 paracrine axis
    • Authors: Xiong, Z., Yu, S.-L., Xie, Z.-X., Huang, H., Li, K.-W.
    • Journal: iScience, 2024, 27(5), 109674

 

  • 🧪 MT1G, an emerging ferroptosis-related gene: A novel prognostic biomarker and indicator of immunotherapy sensitivity in prostate cancer
    • Authors: Cheng, B., Lai, Y., Huang, H., Wang, Q., Huang, H.
    • Journal: Environmental Toxicology, 2024, 39(2), pp. 927–941